NiKem acquires GSK's V-ATPase inhibitors
Executive Summary
Medicinal and combinatorial chemistry services company NiKem Research acquired from GlaxoSmithKline three groups of small molecules (and related patents) which have therapeutic potential across several disease areas.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice